XTRA:SY1Chemicals
Symrise (XTRA:SY1) Valuation After €295 Million Impairments And Potential Terpenes Divestment
Why Symrise’s latest impairments matter for shareholders
Symrise (XTRA:SY1) has put fresh attention on its shares after announcing around €295 million in non-cash impairment charges tied to its terpenes business and its investment in Sweden listed Swedencare AB.
The company is in advanced talks to sell the terpenes unit through a structured bidding process. This triggers IFRS 5 treatment and an impairment of about €145 million in the fourth quarter of 2025, weighing on EBIT.
Separately,...